Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557465 | 0.99 | LMNA (0.59) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL14769256 | 0.97 | LMNA (0.56) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL8378015 | 0.96 | LMNA (0.56) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL9189596 | 0.96 | LMNA (0.56) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL9237406 | 0.95 | LMNA (0.55) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL8905505 | 0.95 | SMN1; SMN2 (0.57) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL8905699 | 0.95 | LMNA (0.55) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL622239 | 0.93 | LMNA (0.54) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL10429709 | 0.93 | LMNA (0.54) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL30980824 | 0.93 | LMNA (0.54) | LMNACYP2C19HIF1ASMN1; SMN2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101973-A1 | IODINATED MULTI-FUNCTIONAL COMPOUNDS WITH ENHANCED HYDROLYTIC STABILITY IN RADIOPAQUE HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260125517-A1 | IODINATED MULTI-FUNCTIONAL COMPOUNDS WITH ENHANCED HYDROLYTIC STABILITY IN RADIOPAQUE HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-07 | — | — | US | claimed |
| WO-2026090138-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108635-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4126814-B1 | CONTINUOUS CRYSTALLISATION METHOD | GE HEALTHCARE AS (NO) | 2024-12-18 | — | — | EP | claimed |
| CN-118993927-A | Synthesis method of 5-acetamido-2, 4, 6-triiodo-N, N' -bis (2, 3-dihydroxypropyl) -1, 3-benzenedicarboxamide | 浙江海洲制药股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-115298162-B | Continuous crystallization process | 通用电气医疗集团股份有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-116421744-A | Absorbable medical hydrogel and preparation method thereof | 杭州融华再生医学科技有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-20230133715-A1 | CONTINUOUS CRYSTALLISATION METHOD | GE HEALTHCARE AS (NO) | 2023-05-04 | — | — | US | claimed |
| CN-115298162-A | Continuous crystallization method | 通用电气医疗集团股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| EP-0925275-B1 | PROCESS FOR IOHEXOL MANUFACTURE | NYCOMED IMAGING AS (NO) | 2001-12-12 | — | — | EP | claimed |
| US-5948940-A | OXYALKYLATION OF5-ACETAMIDO-N,N-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODOPHTHAL IMIDE | NYCOMED IMAGING AS (NO) | 1999-09-07 | — | — | US | claimed |
| US-5847212-A | Process for the preparation of iohexol | ABBOTT LABORATORIES (US) | 1998-12-08 | — | — | US | claimed |
| WO-1998013334-A1 | PROCESS FOR THE PREPARATION OF IOHEXOL | ABBOTT LABORATORIES (US) | 1998-04-02 | — | — | WO | claimed |
| US-5705692-A | Process for the preparation of iohexol | ABBOTT LABORATORIES (US) | 1998-01-06 | — | — | US | claimed |
| EP-0646021-B1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALLINCKRODT MEDICAL INC (US) | 1996-11-27 | — | — | EP | claimed |
| EP-0646021-A1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION. | MALLINCKRODT MEDICAL INC (US) | 1995-04-05 | — | — | EP | claimed |
| EP-0646021-A4 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION. | MALLINCKRODT MEDICAL INC (US) | 1994-10-07 | — | — | EP | claimed |
| US-5210300-A | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALINCKRODT MEDICAL, INC. (US) | 1993-05-11 | — | — | US | claimed |
| WO-1993005820-A1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALLINCKRODT MEDICAL, INC. (US) | 1993-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125517-A1 | IODINATED MULTI-FUNCTIONAL COMPOUNDS WITH ENHANCED HYDROLYTIC STABILITY IN RADIOPAQUE HYDROGELS | MMP1, ILK, MMP13 | LMNA 2390/4885CYP2C19 3586/4885HIF1A 1583/4885 |
| US-20260108635-A1 | ETHER-CONTAINING RADIOPAQUE POLYAMINO CROSSLINKERS AND MEDICAL HYDROGELS FORMED THEREFROM | BRDT, ILK, KLK3 | LMNA 3855/4885CYP2C19 2180/4885HIF1A 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.